Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.30 | N/A | -11.78% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.30 | N/A | -11.78% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing the importance of their ongoing projects. They did not provide any updates on future guidance.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its pipeline despite the current challenges.
Kodiak Sciences reported a larger-than-expected loss per share, which contributed to a decline in its stock price by 3.31%. The lack of revenue figures and guidance may leave investors uncertain about the company's near-term prospects. Management's focus on pipeline development suggests they are prioritizing long-term growth despite current challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
US FOODS HLDG CORP
Nov 8, 2021